Incidence and predictors of hypophosphataemia after ferric carboxymaltose use—A 3‐year experience from a single institution in Singapore

作者：Zachary Chu, Tim Cushway, Marc Wong, Kai Xiong Lim, Wee‐Ming Peh, Choong‐Tatt Ng, Wan Yen Lim, Sharon Ong, Tze‐Tong Tey, Fung Joon Foo, Frederick H. Koh · 发表于：British Journal of Haematology · 年份：2023 · DOI：10.1111/bjh.18979 · 被引用次数：12 · 研究领域：Parathyroid Disorders and Treatments、Erythropoietin and Anemia Treatment、Iron Metabolism and Disorders

Ferric carboxymaltose (FCM) administration helps reduce transfusion requirements in the perioperative situation, which improves patient outcomes and reduces healthcare costs. However, there is increasing evidence of hypophosphataemia after FCM use. We aim to determine the incidence of hypophosphataemia after FCM administration and elucidate potential biochemical factors associated with the development of subsequent hypophosphataemia. A retrospective review of anonymised data of all FCM administrations in a single institution was conducted from August 2018 to August 2021. Each unique FCM dose administered was examined to assess its effect on Hb and serum phosphate levels within the subsequent 28 days from each FCM administration. Phosphate levels were repeatedly measured within the 28-day interval and the lowest phosphate level within that period was determined. Patients' serum phosphate levels within 28 days of FCM administration were compared against normal serum phosphate levels within 2 weeks before FCM administration. The odds ratios of various pre-FCM serum markers were calculated to elucidate potential biochemical predictors of post-FCM hypophosphataemia. In 3 years, a total of 1296 doses of FCM were administered to 1069 patients. The mean improvement in Hb was 2.45 g/dL (SD = 1.94) within 28 days of FCM administration, with the mean time taken to peak Hb levels being 6.3 days (SD = 8.63), which is earlier than expected, but was observed in this study and hence reported...